Bladder Cancer: study on a drug delivery system (TAR-200)Research Question:
Is TAR-200, an investigational drug delivery system, in combination with nivolumab
safe and tolerable in patients with muscle-invasive bladder cancer (MIBC)?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
TAR-200 is a drug-device product that continuously releases a chemotherapy drug (called
gemcitabine) in the bladder over several days. The purpose of this study is to determine
if TAR-200, when combined with a first-line treatment (a drug called nivolumab) is
safe and tolerable in patients with muscle-invasive bladder cancer (MIBC).
Study Reference #: IGUB18046
Lead Researcher (Principal Investigator)
Lead Researcher: Chunkit Fung
Study Contact InformationStudy Coordinator: Park Bogan
Phone: (585) 276-4415
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search